- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06513156
Continuidad de la atención en pacientes hospitalizados con trastorno por consumo de opioides y complicaciones infecciosas por el consumo de drogas (CHOICE-STAR)
La continuidad de la atención en pacientes hospitalizados con trastorno por consumo de opioides y complicaciones infecciosas del consumo de drogas - NavSTAR, tratamiento habitual, clínica integrada de adicción/identificación para prevenir el reingreso relacionado con infecciones
This is a two-group randomized controlled trial conducted at five hospitals across the U.S. designed to test the effectiveness of an Integrated infectious diseases/Substance Use Disorder outpatient clinic (IC) compared to treatment as usual aimed at reducing infection related readmissions and improving health outcomes in people hospitalized with an infection related to injecting opioids or stimulants.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
This is a phase III two arm randomized controlled trial to determine the impact and Integrated infectious diseases (ID) and Substance Use Disorder outpatient clinic (IC) compared to treatment as usual on infection related rehospitalization in individuals hospitalized with infections due to injecting opioids or Stimulants, in the 6 month time period after discharge. This study includes both cost effectiveness and implementation outcomes.
(1) IC will provide facilitated linkage to a clinic providing medical treatment aimed at treating substance use disorder (SUD), resolving the index infection, treating existing ID complications of OUD (HIV, HCV, wounds) and preventing subsequent infections by providing accessible care for infectious diseases and medication for OUD (MOUD) treatment that is integrated into a single appointment and co-located at a single site (either in person or via telemedicine) for a minimum of monthly appointments over a 6 month time period. A feature of the IC will be weekly care coordination meetings between the ID and MOUD providers.
The study will recruit patients during hospitalization for an infection due to injecting opioids or stimulants at four hospital systems (five hospitals) and randomly assign approximately 304 inpatients in 1:1 ratio to IC vs TAU.
Participants will be followed for 12 months.
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Rachel Silk
- Número de teléfono: 301-326-7652
- Correo electrónico: rsilk@ihv.umaryland.edu
Ubicaciones de estudio
-
-
District of Columbia
-
Washington D.C., District of Columbia, Estados Unidos, 20052
- Reclutamiento
- George Washington University
-
Sub-Investigador:
- Irene Kuo, MD
-
Contacto:
- Jill Catalanotti, MD
- Correo electrónico: jcatalanotti@mfa.gwu.edu
-
Investigador principal:
- Jill Catalanotti, MD
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30322
- Reclutamiento
- Emory University
-
Investigador principal:
- Joseph Carpenter, MD
-
Contacto:
- Joseph Carpenter, MD
- Correo electrónico: joseph.edward.carpenter@emory.edu
-
Sub-Investigador:
- Alina Steck, MD
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21201
- Reclutamiento
- University of Maryland Baltimore
-
Sub-Investigador:
- Edward Traver, MD
-
Investigador principal:
- Elana Rosenthal, MD
-
Sub-Investigador:
- Sarah Kattakuzhy, MD
-
Contacto:
- Rachel Silk
- Número de teléfono: 3013267652
- Correo electrónico: rsilk@ihv.umaryland.edu
-
-
West Virginia
-
Morgantown, West Virginia, Estados Unidos, 26506
- Reclutamiento
- West Virginia University
-
Contacto:
- Rebecca Reece, MD
- Correo electrónico: rreece@hsc.wvu.edu
-
Investigador principal:
- Rebecca Reece, MD
-
Sub-Investigador:
- Clinton Cooper, MD
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Age ≥ 18 years
- Admitted to study hospital (defined as hospitalized with a primary team that is not Emergency Medicine)
- Injection opioid or stimulant use in past 90 days - per patient self-report
- Active suspected or confirmed qualifying infection (see list) at time of admission.
Qualifying infections:
- Non-vertebral osteomyelitis
- Vertebral osteomyelitis or discitis
- Epidural, subdural, or extradural abscess
- Intracranial or intraspinal abscess
- Native joint septic arthritis
- Prosthetic joint septic arthritis
- Blood stream infection (bacterial or fungal)
- Native valve Endocarditis
- Prosthetic valve endocarditis
- Cardiac Implantable electronic device infection
- Infectious pseudoaneurysm and aneurysm
- Infected vascular graft
- Septic venous thrombosis
- Skin and Soft tissue infection (cellulitis, skin abscess, necrotizing fasciitis)
- Infected skin ulcer
- Orthopedic hardware infection
- Muscle abscess/myositis
- Central nervous system infection (bacterial or fungal)
- Bacterial or fungal ophthalmologic infection
- Other abscess
- Pulmonary septic emboli
- Other acute bacterial or fungal infection deemed appropriate by site study team
Exclusion Criteria:
-
1. Infection due to a cause other than injection drug use, per determination of a site PI.
2. Inability to provide consent due to circumstance (e.g., sedated, intubated), language, or cognitive impairment.
3. Unwilling to provide informed consent 4. Unable to receive potential interventions due to geography 5. On comfort measures or planned for discharge to hospice care 6. Incarcerated at the time of hospitalization 7. Other criteria at the discretion of the site investigator
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Sin intervención: Treatment As Usual
Will receive treatment for infection and opioid or stimulant use disorder per the usual care at each hospital |
|
|
Experimental: Integrated Infectious Diseases and Substance Use Disorder Clinic (IC)
The Integrated ID/SUD Clinic will provide facilitated linkage to a clinic providing medical treatment aimed at treating SUD, resolving the sentinel infection, treating existing ID complications of OUD/stimulants (HIV, HCV, wounds) and preventing subsequent infections by providing accessible care for infectious diseases and MOUD treatment that is integrated into a single appointment and co-located at a single site (either in person or via telemedicine) for a minimum of monthly appointments over a 6 month time period. A feature of the IC will be weekly care coordination meetings between the ID and SUD providers. The dual goals of the IC intervention are to 1) to facilitate accessibility to ID and OUD care and 2) to ensure care coordination between outpatient ID and SUD providers. |
Integrated medication for opioid/stimulant use disorder and infectious disease care provided into single appointment either in person or via telemedicine with a minimum of monthly appointments for 6 months. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Infection Rehospitalization
Periodo de tiempo: 6 months after discharge for index hospitalization
|
New hospitalization due to infection following discharge for index hospitalization |
6 months after discharge for index hospitalization
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Time to first infection related readmission
Periodo de tiempo: 12 months after discharge for index hospitalization
|
Time to first infection related readmission |
12 months after discharge for index hospitalization
|
|
Reason for infection related readmission
Periodo de tiempo: 12 months after discharge for index hospitalization
|
Reason for infection related readmission (persistent index infection, new IDU associated infection, other infection) |
12 months after discharge for index hospitalization
|
|
Hospital services utilization
Periodo de tiempo: 12 months after discharge for index hospitalization
|
ED visits (Binary, count, time to first ED visit, cause) and Readmission, all cause (binary, count, time to first readmission, cause) |
12 months after discharge for index hospitalization
|
|
Mortality
Periodo de tiempo: 12 months after discharge for index hospitalization
|
Death (Binary, time to death, cause of death) |
12 months after discharge for index hospitalization
|
|
Index infection
Periodo de tiempo: 3 months after discharge for index hospitalization
|
Completion of antibiotics (binary, reason for incomplete antibiotics); Resolution of index infection (binary) Skilled Nursing Facility (SNF) Admitted to SNF (binary) Discharge type from SNF (planned, PDD, dead, transfer) |
3 months after discharge for index hospitalization
|
|
Other Infections
Periodo de tiempo: 12 months after discharge for index hospitalization
|
HCV Active HCV (binary) Clinical evaluation (binary) DAA prescribed (binary) DAA initiated (binary) SVR achieved (binary) HIV Diagnosis status (binary) HIV VL undetectable (binary) ART Taking (binary) Type (pills vs injections) Adherence (# missed doses in last 30 days) PrEP Eligible (CDC Criteria, binary, indication) Offered by healthcare provider (binary) Taking (binary) Type (pills vs injections) Adherence (# missed doses in last 30 days) |
12 months after discharge for index hospitalization
|
|
Skin and soft tissue wounds
Periodo de tiempo: 12 months after discharge for index hospitalization
|
Present (binary) Number (count) Per wound Size Location on body Duration (continuous) |
12 months after discharge for index hospitalization
|
|
New infections not requiring hospitalization
Periodo de tiempo: 12 months after discharge for index hospitalization
|
|
12 months after discharge for index hospitalization
|
|
Outpatient linkage and retention
Periodo de tiempo: 12 months after discharge for index hospitalization
|
|
12 months after discharge for index hospitalization
|
|
Medication for Opioid Use (MOUD)
Periodo de tiempo: 12 months after discharge for index hospitalization
|
|
12 months after discharge for index hospitalization
|
|
Medication for stimulant use (MStUD)
Periodo de tiempo: 12 months after discharge for index hospitalization
|
|
12 months after discharge for index hospitalization
|
|
Substance Use-Opioid
Periodo de tiempo: 12 months after discharge for index hospitalization
|
Ongoing opioid (binary, mode)
|
12 months after discharge for index hospitalization
|
|
Substance Use - Stimulant
Periodo de tiempo: 12 months after discharge for index hospitalization
|
Ongoing stimulant use (binary, mode)
|
12 months after discharge for index hospitalization
|
|
Cost Effectiveness
Periodo de tiempo: 12 months after discharge for index hospitalization
|
• ICER for quality adjusted life years (QALYs); opioid-free years (OfYs); and infection-free years (IfYs) gained |
12 months after discharge for index hospitalization
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Elana Rosenthal, MD, University of Maryland, Baltimore
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- HP-00111318
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .